UroGen Pharma (URGN) Long-Term Deferred Tax (2023 - 2025)
UroGen Pharma's (URGN) quarterly Long-Term Deferred Tax came in at $153.4 million in Q4 2025, up 24.73% YoY from $122.9 million in Q4 2024, and up 24.73% on a QoQ basis from $122.9 million in Q4 2024.
UroGen Pharma (URGN) Long-Term Deferred Tax (2023 - 2025) Analysis & Trends
UroGen Pharma (URGN) has 3 years of Long-Term Deferred Tax data on file, last reported at $153.4 million in Q4 2025.
- Quarterly Long-Term Deferred Tax rose 24.73% year-over-year to $153.4 million in Q4 2025, while the trailing twelve-month figure through Dec 2025 was $153.4 million (up 24.73% YoY) and the FY2025 annual result came in at $153.4 million, up 24.73% from the prior year.
- Long-Term Deferred Tax rose to $153.4 million in Q4 2025, from $122.9 million in the prior quarter.
- In the past five years, Long-Term Deferred Tax ranged from a high of $153.4 million in Q4 2025 to a low of $103.6 million in Q4 2023.
- A 3-year average of $126.6 million and a median of $122.9 million in 2024 frame the typical range for Long-Term Deferred Tax.
- Annual changes were most pronounced in 2024 — Long-Term Deferred Tax rose 18.71% — and 2025, when it rose 24.73%.
- Tracing URGN's Long-Term Deferred Tax over 3 years: stood at $103.6 million in 2023, then climbed by 18.71% to $122.9 million in 2024, then advanced by 24.73% to $153.4 million in 2025.
- The last three Long-Term Deferred Tax figures came in at $153.4 million (Q4 2025), $122.9 million (Q4 2024), and $103.6 million (Q4 2023), per Business Quant data.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn |
| 10 | UroGen Pharma | 2.36 Bn | 2.25 Bn | 65.88 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2025 | 153.35 Mn |
| Dec 31, 2024 | 122.94 Mn |
| Dec 31, 2023 | 103.57 Mn |